托伐普坦治疗肝硬化顽固性腹水并低钠血症的疗效
Efficacy of tolvaptan in the treatment of cirrhosis complicated with refractory ascites and hyponatremia

DOI: 10.6040/j.issn.1671-7554.0.2015.392

Keywords: 托伐普坦,肝硬化,低钠血症,顽固性腹水,
Tolvaptan,Refractory ascites,Hyponatremia,Cirrhosis

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. NEngl J Med, 2006, 355(20):2099-2112.
[2]	Okita K, Sakaida l, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis[J]. J Gastroenterol, 2010, 45(9):979-987.
[3]	Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists[J]. Heart Fail Rev, 2009, 14(2):75-82.
[4]	Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia[J]. J Am Soc Nephrol, 2010, 21(4):705-712.
[5]	Dasta JF, Chiong JR, Christian R, et al. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials[J]. Hosp Pract, 2012, 40(1):7-14.
[6]	Cho C, Logan JL, Lien YH. Massive aquaresis after tolvaptan administration and albumin infusion in a patient with alcoholic cirrhosis[J]. Am J Med, 2012, 125(1):5-6.
[7]	Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites[J]. Hepatology, 2004, 40(3):629-635.
[8]	中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 中华实验和临床感染病杂志: 电子版, 2011, 1:79-100.
[9]	Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists[J]. Drugs, 2007, 67(6):847-858.
[10]	高倩.托伐普坦片治疗低钠血症的效果及安全性观察[J]. 实用医药杂志, 2011, 28(5):387-389. GAO Qian. Efficacy and safety of tolvaptan in the treatment of hyponatremia[J]. Practical Journal of Medicine & Pharmacy, 2011, 28(5):387-389.
[11]	Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis[J]. J Hepatol, 2012, 56(3):571-578.
[12]	Doggrell SA. Tolvaptan(Otsuka)[J]. Curr Opin Investig Drugs, 2004, 5(9):977-983.
[13]	Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J]. Hepatology, 1996, 23(1):164-176.
[14]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3):397-417.
[15]	Lehrich RW, Greenberg A. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients[J]. J Intensive Care Med, 2012, 27(4):207-218.
[16]	Habib S, Boyer TD. Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia[J]. Therap Adv Gastroenterol, 2012, 5(3):189-197.

Full-Text